Follicular lymphoma: an update on diagnosis, prognosis, and management

Med Clin (Barc). 2021 Nov 12;157(9):440-448. doi: 10.1016/j.medcli.2021.03.041. Epub 2021 Jun 29.
[Article in English, Spanish]

Abstract

Follicular lymphoma, the most common indolent lymphoma, originates from germinal centre B-cells of the lymphoid follicle, and is characterized by t(14;18). Clinical manifestations include the presence of lymphadenopathy, sometimes accompanied by constitutional symptoms or cytopenia. Diagnosis is established through the identification of a B-cell proliferation of nodular pattern in the lymph node biopsy. Upon staging with PET-CT and bone marrow biopsy, a significant proportion of patients do not need immediate treatment. When therapy is indicated, commonly used regimens include anti-CD20 immunotherapy with or without chemotherapy. Although overall survival for most patients is prolonged, relapses are very frequent, and early relapse and transformation to an aggressive lymphoma portend a much worse prognosis. New therapies are under development, which will most likely change outcomes for FL patients in the near future.

Keywords: Diagnosis; Diagnóstico; Follicular lymphoma; Immunochemotherapy; Inmunoquimioterapia; Linfoma folicular; Prognosis; Pronóstico; Tratamiento; Treatment.

Publication types

  • Review

MeSH terms

  • Humans
  • Lymphoma, Follicular* / diagnosis
  • Lymphoma, Follicular* / therapy
  • Lymphoma, Non-Hodgkin*
  • Neoplasm Recurrence, Local
  • Positron Emission Tomography Computed Tomography
  • Prognosis